clinical trial · NCT04076462
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly
AcromegalyCAM2029 (octreotide subcutaneous depot)Matching placebo
brief summary
The purpose of this trial is to assess the efficacy and safety of CAM2029 in patients with acromegaly. Patients will be randomized to either CAM2029 or placebo administered subcutaneously once monthly during 6 months.
started
Aug 19, 2019
primary completion
May 2, 2023
completion
May 2, 2023
last updated
Apr 25, 2024
official title
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multi-center Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) in Patients With Acromegaly
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol